Other Species / Isoforms
  PKN2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S3
_____MAsNPERGEI
0 3
PKN2 (human) _____MAsNPERGEI S3
PKN2 iso2 (human) _____MASNPERGEI S3
PKN2 (mouse) _____MAsNPDRGEI S3
PKN2 (rat) _____MASNPDRGEI S3
S21
ELQGDSRsLPFSENV
0 4
PKN2 (human) ELQGDSRsLPFSENV S21
PKN2 iso2 (human) ELQGDSRSLPFSENV S21
PKN2 (mouse) ELQGDSRTLPFSENV T21
PKN2 (rat) ELQVDSRPLPFSENV P21
S29
LPFSENVsAVQKLDF
0 1
PKN2 (human) LPFSENVsAVQKLDF S29
PKN2 iso2 (human) LPFSENVSAVQKLDF S29
PKN2 (mouse) LPFSENVSAVQKLDF S29
PKN2 (rat) LPFSENVSAVQKLDF S29
S110
LNAHIVVsDPEDITD
Upstream
0 20
Treatment
  • MLN8054
PKN2 (human) LNAHIVVsDPEDITD S110
PKN2 iso2 (human) LNAHIVVSDPEDITD S110
PKN2 (mouse) LNAHIVVsDPEDSTD S110
PKN2 (rat) LNAHIVVSDPEDYTD S110
T121
DITDCPRtPDtPNND
Upstream
0 7
Treatment
  • MLN8054
PKN2 (human) DITDCPRtPDtPNND T121
PKN2 iso2 (human) DITDCPRTPDTPNND T121
PKN2 (mouse) DSTDCPRtPDTPNSD T121
PKN2 (rat) DYTDCPRTPDTPNSD T121
T124
DCPRtPDtPNNDPRC
Upstream
0 8
Treatment
  • MLN8054
PKN2 (human) DCPRtPDtPNNDPRC T124
PKN2 iso2 (human) DCPRTPDTPNNDPRC T124
PKN2 (mouse) DCPRtPDTPNSDSRS T124
PKN2 (rat) DCPRTPDTPNSDSRS T124
S163
ENMIQMYsNGSSKDR
0 1
PKN2 (human) ENMIQMYsNGSSKDR S163
PKN2 iso2 (human) ENMIQMYSNGSSKDR S163
PKN2 (mouse) ENMIQMYSNGSSKDR S163
PKN2 (rat) ENMIQMYSNGPSKDR S164
S255
VTDRKALsEAQARFN
Upstream
0 1
Treatment
  • nocodazole
PKN2 (human) VTDRKALsEAQARFN S255
PKN2 iso2 (human) VTDRKALSEAQARFN S255
PKN2 (mouse) VTDRKALSEAQARFN S255
PKN2 (rat) VTDRKALSEAQARFN S257
S264
AQARFNEsSQKLDLL
0 1
PKN2 (human) AQARFNEsSQKLDLL S264
PKN2 iso2 (human) AQARFNESSQKLDLL S264
PKN2 (mouse) AQARFNESSQKLDLL S264
PKN2 (rat) AQARFNESSQKLDLL S266
Y273
QKLDLLKysLEQRLN
0 1
PKN2 (human) QKLDLLKysLEQRLN Y273
PKN2 iso2 (human) QKLDLLKYSLEQRLN Y273
PKN2 (mouse) QKLDLLKYSLEQRLN Y273
PKN2 (rat) QKLDLLKYSLEQRLN Y275
S274
KLDLLKysLEQRLNE
0 1
PKN2 (human) KLDLLKysLEQRLNE S274
PKN2 iso2 (human) KLDLLKYSLEQRLNE S274
PKN2 (mouse) KLDLLKYSLEQRLNE S274
PKN2 (rat) KLDLLKYSLEQRLNE S276
S289
VPKNHPKsRIIIEEL
0 2
PKN2 (human) VPKNHPKsRIIIEEL S289
PKN2 iso2 (human) VPKNHPKSRIIIEEL S289
PKN2 (mouse) LPRNHPKSSVVIEEL S289
PKN2 (rat) LPKNHPKSSVVIEEL S291
S302
ELSLVAAsPtLsPRQ
Upstream
0 10
Treatment
  • ischemia
  • nocodazole
  • thymidine
view more >
PKN2 (human) ELSLVAAsPtLsPRQ S302
PKN2 iso2 (human) ELSLVAASPTLSPRQ S302
PKN2 (mouse) EELSLVASPTLsPRQ S301
PKN2 (rat) EELSLVASPTLSPRQ S303
T304
SLVAAsPtLsPRQsM
0 2
PKN2 (human) SLVAAsPtLsPRQsM T304
PKN2 iso2 (human) SLVAASPTLSPRQSM T304
PKN2 (mouse) LSLVASPTLsPRQSM T303
PKN2 (rat) LSLVASPTLSPRQSM T305
S306
VAAsPtLsPRQsMIS
Upstream
0 16
Treatment
  • nocodazole
  • thymidine
PKN2 (human) VAAsPtLsPRQsMIS S306
PKN2 iso2 (human) VAASPTLSPRQSMIS S306
PKN2 (mouse) LVASPTLsPRQSMLS S305
PKN2 (rat) LVASPTLSPRQSMLS S307
S310
PtLsPRQsMISTQNQ
0 2
PKN2 (human) PtLsPRQsMISTQNQ S310
PKN2 iso2 (human) PTLSPRQSMISTQNQ S310
PKN2 (mouse) PTLsPRQSMLSTQNQ S309
PKN2 (rat) PTLSPRQSMLSTQNQ S311
Y318
MISTQNQySTLSKPA
0 1
PKN2 (human) MISTQNQySTLSKPA Y318
PKN2 iso2 (human) MISTQNQYSTLSKPA Y318
PKN2 (mouse) MLSTQNQYSTLSKPA Y317
PKN2 (rat) MLSTQNQYSTLSKPA Y319
S349
LENVPGRsKATSVAL
0 1
PKN2 (human) LENVPGRsKATSVAL S349
PKN2 iso2 (human) LENVPGRSKATSVAL S349
PKN2 (mouse) LENVPGRSKATSVAL S348
PKN2 (rat) WENVPGRSKATSVAL S350
S360
SVALPGWsPsETRSs
Upstream
0 21
Treatment
  • MG132_withdrawal
  • nocodazole
PKN2 (human) SVALPGWsPsETRSs S360
PKN2 iso2 (human) SVALPGWsPSETRSS S360
PKN2 (mouse) SVALPGWsPSDNRSs S359
PKN2 (rat) SVALPGWSPSENRSS S361
S362
ALPGWsPsETRSsFM
0 1
PKN2 (human) ALPGWsPsETRSsFM S362
PKN2 iso2 (human) ALPGWsPSETRSSFM S362
PKN2 (mouse) ALPGWsPSDNRSsFM S361
PKN2 (rat) ALPGWSPSENRSSFM S363
S367
sPsETRSsFMsRTSK
0 4
PKN2 (human) sPsETRSsFMsRTSK S367
PKN2 iso2 (human) sPSETRSSFMSRTSK S367
PKN2 (mouse) sPSDNRSsFMSRTSK S366
PKN2 (rat) SPSENRSSFMSRTSK S368
S370
ETRSsFMsRTSKSKS
0 2
PKN2 (human) ETRSsFMsRTSKSKS S370
PKN2 iso2 (human) ETRSSFMSRTSKNDV S370
PKN2 (mouse) DNRSsFMSRTSKSKS S369
PKN2 (rat) ENRSSFMSRTSKSKS S371
S379
TSKSKSGsSRNLLKT
0 2
PKN2 (human) TSKSKSGsSRNLLKT S379
PKN2 iso2 (human) gap -
PKN2 (mouse) TSKSKSGSSRNLLKT S378
PKN2 (rat) TSKSKSGSSRNLLKT S380
S408
NTVVGQTsWKPIsNQ
0 1
PKN2 (human) NTVVGQTsWKPIsNQ S408
PKN2 iso2 (human) NTVVGQTSWKPISNQ S392
PKN2 (mouse) NTVVGQTSWKPISNQ S407
PKN2 (rat) NTVVGQTIWKPISNQ I409
S413
QTsWKPIsNQsWDQK
0 1
PKN2 (human) QTsWKPIsNQsWDQK S413
PKN2 iso2 (human) QTSWKPISNQSWDQK S397
PKN2 (mouse) QTSWKPISNQSWDQK S412
PKN2 (rat) QTIWKPISNQSWDQK S414
S416
WKPIsNQsWDQKFTL
0 1
PKN2 (human) WKPIsNQsWDQKFTL S416
PKN2 iso2 (human) WKPISNQSWDQKFTL S400
PKN2 (mouse) WKPISNQSWDQKFTL S415
PKN2 (rat) WKPISNQSWDQKFTL S417
S497
QRQKKIFsKQQGKtF
0 7
PKN2 (human) QRQKKIFsKQQGKtF S497
PKN2 iso2 (human) QRQKKIFSKQQGKTF S481
PKN2 (mouse) QRQKKIFsKQQGKTF S496
PKN2 (rat) QRQKKIFSKQQGKTF S498
T503
FsKQQGKtFLRAPQM
0 1
PKN2 (human) FsKQQGKtFLRAPQM T503
PKN2 iso2 (human) FSKQQGKTFLRAPQM T487
PKN2 (mouse) FsKQQGKTFLRAPQM T502
PKN2 (rat) FSKQQGKTFLRAPQM T504
T516
QMNINIAtWGRLVRR
0 3
PKN2 (human) QMNINIAtWGRLVRR T516
PKN2 iso2 (human) QMNINIATWGRLVRR T500
PKN2 (mouse) QMNINIATWGRLVRR T515
PKN2 (rat) QMNINIATWGRLVRR T517
S531
AIPTVNHsGtFsPQA
0 2
PKN2 (human) AIPTVNHsGtFsPQA S531
PKN2 iso2 (human) AIPTVNHSGTFSPQA S515
PKN2 (mouse) AIPTVNHSGTFsPQt S530
PKN2 (rat) AIPTVNHSGTFSPQT S532
T533
PTVNHsGtFsPQAPV
0 1
PKN2 (human) PTVNHsGtFsPQAPV T533
PKN2 iso2 (human) PTVNHSGTFSPQAPV T517
PKN2 (mouse) PTVNHSGTFsPQtPV T532
PKN2 (rat) PTVNHSGTFSPQTPV T534
S535
VNHsGtFsPQAPVPT
Upstream
0 11
Kinase, in vitro:
  • CDK1 (human)
Treatment
  • nocodazole
PKN2 (human) VNHsGtFsPQAPVPT S535
PKN2 iso2 (human) VNHSGTFSPQAPVPT S519
PKN2 (mouse) VNHSGTFsPQtPVPA S534
PKN2 (rat) VNHSGTFSPQTPVPA S536
A538
sGtFsPQAPVPTTVP
0 1
PKN2 (human) sGtFsPQAPVPTTVP A538
PKN2 iso2 (human) SGTFSPQAPVPTTVP A522
PKN2 (mouse) SGTFsPQtPVPATVP T537
PKN2 (rat) SGTFSPQTPVPATVP T539
S559
PQLAPPAsDsTVTKL
0 1
PKN2 (human) PQLAPPAsDsTVTKL S559
PKN2 iso2 (human) PQLAPPASDSTVTKL S543
PKN2 (mouse) PDLAPPASDSTVTKL S558
PKN2 (rat) PELAPPASDSTVTKL S560
S561
LAPPAsDsTVTKLDF
0 1
PKN2 (human) LAPPAsDsTVTKLDF S561
PKN2 iso2 (human) LAPPASDSTVTKLDF S545
PKN2 (mouse) LAPPASDSTVTKLDF S560
PKN2 (rat) LAPPASDSTVTKLDF S562
S582
PPAPPRAssLGEIDE
0 14
PKN2 (human) PPAPPRAssLGEIDE S582
PKN2 iso2 (human) PPAPPRASSLGEIDE S566
PKN2 (mouse) PPAPPRAssLGETDE S581
PKN2 (rat) PPAPPRAssLGEIDD S583
S583
PAPPRAssLGEIDES
Upstream
0 61
Treatment
  • EGF
  • ischemia
  • metastatic potential
  • nocodazole
  • SB202190
  • selumetinib
  • U0126
  • vemurafenib
view more >
PKN2 (human) PAPPRAssLGEIDES S583
PKN2 iso2 (human) PAPPRASSLGEIDES S567
PKN2 (mouse) PAPPRAssLGETDES S582
PKN2 (rat) PAPPRAssLGEIDDS S584
S603
LDIPGQDsETVFDIQ
0 1
PKN2 (human) LDIPGQDsETVFDIQ S603
PKN2 iso2 (human) LDIPGQDSETVFDIQ S587
PKN2 (mouse) LDIPGQGSETVFNIE S602
PKN2 (rat) LDIPGQGSETVFDIE S604
S615
DIQNDRNsILPKSQS
Upstream
0 4
Treatment
  • nocodazole
PKN2 (human) DIQNDRNsILPKSQS S615
PKN2 iso2 (human) DIQNDRNSILPKSQS S599
PKN2 (mouse) NIENDRNNLRPKsKs N614
PKN2 (rat) DIENDRNNMRPKSKS N616
S620
RNsILPKSQSEyKPD
0 5
PKN2 (human) RNsILPKSQSEyKPD S620
PKN2 iso2 (human) RNSILPKSQSEYKPD S604
PKN2 (mouse) RNNLRPKsKsEyELS S619
PKN2 (rat) RNNMRPKSKSEYELN S621
S622
sILPKSQSEyKPDtP
0 4
PKN2 (human) sILPKSQSEyKPDtP S622
PKN2 iso2 (human) SILPKSQSEYKPDTP S606
PKN2 (mouse) NLRPKsKsEyELSIP S621
PKN2 (rat) NMRPKSKSEYELNIP S623
Y624
LPKSQSEyKPDtPQs
0 8
PKN2 (human) LPKSQSEyKPDtPQs Y624
PKN2 iso2 (human) LPKSQSEYKPDTPQS Y608
PKN2 (mouse) RPKsKsEyELSIPDS Y623
PKN2 (rat) RPKSKSEYELNIPDS Y625
T628
QSEyKPDtPQsGLEy
Upstream
0 11
Treatment
  • BI2536
PKN2 (human) QSEyKPDtPQsGLEy T628
PKN2 iso2 (human) QSEYKPDTPQSGLEY T612
PKN2 (mouse) KsEyELSIPDSGRSC I627
PKN2 (rat) KSEYELNIPDSSRSC I629
S631
yKPDtPQsGLEysGI
Upstream
0 9
Treatment
  • BI2536
PKN2 (human) yKPDtPQsGLEysGI S631
PKN2 iso2 (human) YKPDTPQSGLEYSGI S615
PKN2 (mouse) yELSIPDSGRSCWGV S630
PKN2 (rat) YELNIPDSSRSCWSV S632
Y635
tPQsGLEysGIQELE
Upstream
0 101
Treatment
  • AZD1152
  • Su11274
  • ZM447439
view more >
PKN2 (human) tPQsGLEysGIQELE Y635
PKN2 iso2 (human) TPQSGLEYSGIQELE Y619
PKN2 (mouse) IPDSGRSCWGVGELD C634
PKN2 (rat) IPDSSRSCWSVGELE C636
S636
PQsGLEysGIQELED
0 8
PKN2 (human) PQsGLEysGIQELED S636
PKN2 iso2 (human) PQSGLEYSGIQELED S620
PKN2 (mouse) PDSGRSCWGVGELDD W635
PKN2 (rat) PDSSRSCWSVGELED W637
S646
QELEDRRsQQRFQFN
0 5
PKN2 (human) QELEDRRsQQRFQFN S646
PKN2 iso2 (human) QELEDRRSQQRFQFN S630
PKN2 (mouse) GELDDKRAQQRFQFS A645
PKN2 (rat) GELEDKRSQQRFQFN S647
Y676
GKVLLAEyKNTNEMF
0 4
PKN2 (human) GKVLLAEyKNTNEMF Y676
PKN2 iso2 (human) GKVLLAEYKNTNEMF Y660
PKN2 (mouse) GKVLLAEYKHTNEMF Y675
PKN2 (rat) GKVLLAEYKHTNEMF Y677
S701
VARDEVDsLMCEKRI
0 1
PKN2 (human) VARDEVDsLMCEKRI S701
PKN2 iso2 (human) VARDEVDSLMCEKRI S685
PKN2 (mouse) VARDEVDSLMCEKRI S700
PKN2 (rat) VARDEVDSLMCEKRI S702
T729
NLFACFQtKEHVCFV
0 1
PKN2 (human) NLFACFQtKEHVCFV T729
PKN2 iso2 (human) NLFACFQTKEHVCFV T713
PKN2 (mouse) NLFACFQtKEHVCFV T728
PKN2 (rat) NLFACFQTKEHVCFV T730
T792
LDNLLLDtEGFVKIA
0 1
PKN2 (human) LDNLLLDtEGFVKIA T792
PKN2 iso2 (human) LDNLLLDTEGFVKIA T776
PKN2 (mouse) LDNLLLDTEGFVKIA T791
PKN2 (rat) LDNLLLDTEASVKIA T793
Y810
LCKEGMGyGDRtstF
0 3
PKN2 (human) LCKEGMGyGDRtstF Y810
PKN2 iso2 (human) LCKEGMGYGDRTSTF Y794
PKN2 (mouse) LCKEGMGyGDRtstF Y809
PKN2 (rat) LCKEGMGYGDRtStF Y811
T814
GMGyGDRtstFCGtP
Downstream
1 77
Effects on Modified Protein
  • enzymatic activity, induced
PKN2 (human) GMGyGDRtstFCGtP T814
PKN2 iso2 (human) GMGYGDRTSTFCGTP T798
PKN2 (mouse) GMGyGDRtstFCGtP T813
PKN2 (rat) GMGYGDRtStFCGTP T815
S815
MGyGDRtstFCGtPE
Downstream
1 39
Effects on Modified Protein
  • enzymatic activity, induced
PKN2 (human) MGyGDRtstFCGtPE S815
PKN2 iso2 (human) MGYGDRTSTFCGTPE S799
PKN2 (mouse) MGyGDRtstFCGtPE S814
PKN2 (rat) MGYGDRtStFCGTPE S816
T816
GyGDRtstFCGtPEF
Upstream
Downstream
5 296
PKN2 (human)
T816
PKN2 (mouse)
T815
PKN2 (rat)
T817
Effects on Modified Protein
  • enzymatic activity, induced
Putative in vivo kinases:
  • PDK1 (human)
Treatment
  • brimonidine
  • LY294002
  • U46619
view more >
PKN2 (human) GyGDRtstFCGtPEF T816
PKN2 iso2 (human) GYGDRTSTFCGTPEF T800
PKN2 (mouse) GyGDRtstFCGtPEF T815
PKN2 (rat) GYGDRtStFCGTPEF T817
T820
RtstFCGtPEFLAPE
0 10
PKN2 (human) RtstFCGtPEFLAPE T820
PKN2 iso2 (human) RTSTFCGTPEFLAPE T804
PKN2 (mouse) RtstFCGtPEFLAPE T819
PKN2 (rat) RtStFCGTPEFLAPE T821
S944
IRGREDVSNFDDEFT
0 1
PKN2 (human) IRGREDVSNFDDEFT S944
PKN2 iso2 (human) IRGREDVSNFDDEFT S928
PKN2 (mouse) IRGREDVsNFDDEFT S943
PKN2 (rat) IRGREDVSNFDDEFT S945
S952
NFDDEFTsEAPILtP
0 1
PKN2 (human) NFDDEFTsEAPILtP S952
PKN2 iso2 (human) NFDDEFTSEAPILTP S936
PKN2 (mouse) NFDDEFTSEAPILtP S951
PKN2 (rat) NFDDEFTSEAPILtP S953
T958
TsEAPILtPPREPRI
Upstream
Downstream
3 67
Effects on Modified Protein
  • enzymatic activity, induced
  • enzymatic activity, inhibited
  • molecular association, regulation
  • phosphorylation
  • protein conformation
Effects on Biological Processes:
  • signaling pathway regulation
Kinase, in vitro:
  • mTOR (human)
Putative in vivo kinases:
  • mTOR (human)
Regulatory protein:
  • CD38 (human)
Treatment
  • metastatic potential
  • siRNA
  • torin_2
view more >
PKN2 (human) TsEAPILtPPREPRI T958
PKN2 iso2 (human) TSEAPILTPPREPRI T942
PKN2 (mouse) TSEAPILtPPREPRI T957
PKN2 (rat) TSEAPILtPPREPRI T959
S967
PREPRILsEEEQEMF
0 1
PKN2 (human) PREPRILsEEEQEMF S967
PKN2 iso2 (human) PREPRILSEEEQEMF S951
PKN2 (mouse) PREPRILLEEEQEMF L966
PKN2 (rat) PREPRILLEEEQEMF L968